| Report | Options implied | Actual move | Market was |
|---|---|---|---|
| 07/29/2026 | ±3.3% | +12.2% | under-priced |
| 04/29/2026 | ±2.9% | -13.2% | under-priced |
| 10/29/2025 | ±1.8% | -2.5% | under-priced |
| 07/30/2025 | ±2.0% | -7.8% | under-priced |
| 04/30/2025 | ±4.3% | +3.3% | over-priced |
| 10/30/2024 | ±2.4% | +2.3% | over-priced |
| 07/31/2024 | ±2.4% | +2.4% | over-priced |
| 04/30/2024 | ±2.4% | -14.3% | under-priced |
| Quarter | EPS (dil.) | Revenue | Net income |
|---|---|---|---|
| Q2 FY2026 | $1.24 | $5.3B | $573M |
| Q1 FY2026 | $0.85 | $5.1B | $411M |
| Q4 FY2025 | $1.29 | $5.7B | $602M |
| Q3 FY2025 | $0.98 | $5.1B | $464M |
GE HealthCare Technologies Inc. Common Stock (GEHC) reports in 68 days, with the next report estimated for 11/19/2026. Across the last 8 reports, options priced an average ±2.7% earnings move while the stock actually moved 7.2% on average — the market has been roughly fair on GEHC's earnings risk. Fundamentals into the print: EPS up 17.0% year-over-year, revenue up 5.8%. QuantLogix's live 5-factor engine currently reads GEHC as a underweight at 41/100.
Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →